Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $10 from $13 and keeps a Buy rating on the shares. The target cut reflects a education in the probability of approval in the PKP2 arena, the analyst tells investors in a research note. The firm believes the Street is not yet convinced by Lexeo’s PKP2 data.